Screener
Immunome IMNM Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The source filing: Immunome’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344636
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $5,996 | $3,339 |
| Accrued expenses and other current liabilities | 29,717 | 41,651 |
| Total current liabilities | 35,713 | 44,990 |
| Operating lease liabilities, net of current portion | 4,588 | 3,855 |
| Total liabilities | 40,301 | 48,845 |
| Stockholders’ equity: |
Item 1. Financial Statements.
FAQ
- What is Immunome's accrued expenses?
- Immunome (IMNM) reported accrued expenses of $29.72M in Q2 2026.
- How has Immunome's accrued expenses changed year-over-year?
- Immunome's accrued expenses increased by 63.1% year-over-year, from $18.22M to $29.72M.
- What is the long-term trend for Immunome's accrued expenses?
- Over 5 years (2020 to 2025), Immunome's accrued expenses has grown at a 97.9% compound annual growth rate (CAGR), from $1.37M to $41.65M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Immunome's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude